ArticleInternational journal of cell biology and physiology2018
Immunomodulatory effects of tacrolimus (FK506) for the treatment of allergic diseases.
Article in International journal of cell biology and physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- The impact of tacrolimus therapy on the outcomes of vernal keratoconjunctivitis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- mRNA-1273 COVID-19 vaccine induces CD4+ T-cell responses among solid organ transplant recipients.Frontiers in immunology · 2025Trial
- Severe Hair Dye Anaphylaxis Caused by Toluene-2,5- Diamine Identified by Positive in Vitro Tests.Contact dermatitis · 2026Article
- Injectable Thermoresponsive Dual Nanocarrier Hydrogel for Local Tacrolimus Delivery with a Two-Phase Release Profile.Pharmaceutics · 2026Article
- Neurogranin negatively regulates gene expression and proinflammatory mediator release in allergen-activated mast cells.ImmunoHorizons · 2026Article
- Article
- Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy.Frontiers in pharmacology · 2023Article
- Characterization and In Vitro and In Vivo Evaluation of Tacrolimus-Loaded Poly(ε-Caprolactone) Nanocapsules for the Management of Atopic Dermatitis.Pharmaceutics · 2021Article
- Tacrolimus (FK506) treatment protects allergen-, IL-5- and IL-13-induced mucosal eosinophilia.Immunology · 2021Article
- Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.Cytokine & growth factor reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Tacrolimus has been used to prevent allograft rejection and also used in kidney, liver and heart transplantations. Various preclinical and clinical studies demonstrated that Tacrolimus possess immunomodulatory and anti-inflammatory properties. The mechanism of action of Tacrolimus in allergic diseases involves calcineurin inhibition, and downregulation of T-cell reactivity, IgE degranulation, and its actions on mast cells, dendritic cells, basophils, eosinophils and inhibition of transcription of proinflammatory cytokines. Herein we reviewed the Pharmacotherapeutic mechanism of action of Tacrolimus in the prevention of asthma, atopic dermatitis, and allergic conjunctivitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.